Ionis Pharmaceuticals, Inc的合作伙伴葛兰素史克宣布,其针对慢性乙型肝炎的潜在首创药物Bepirovirsen,在三期临床研究B-Well 1和B-Well 2中取得了积极的顶线结果。这项关键进展标志着该疗法在追求功能性治愈慢性乙肝的道路上迈出了重要一步。
Ionis Pharmaceuticals, Inc的合作伙伴葛兰素史克宣布,其针对慢性乙型肝炎的潜在首创药物Bepirovirsen,在三期临床研究B-Well 1和B-Well 2中取得了积极的顶线结果。这项关键进展标志着该疗法在追求功能性治愈慢性乙肝的道路上迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.